{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:30:15Z","timestamp":1793813415716,"version":"4.6.1"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC-2610280"],"award-info":[{"award-number":["NCC-2610280"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mtbio.2026.103737","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:15:40Z","timestamp":1791389740000},"page":"103737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering immune cell engagers: From molecular constructs to biomaterial platforms"],"prefix":"10.1016","volume":"41","author":[{"given":"Hee Won","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2838-7876","authenticated-orcid":false,"given":"Sungjun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog. Ther."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural Killer cells at the frontline in the fight against cancer","volume":"15","author":"Co\u00ebnon","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mtbio.2026.103737_bib3","article-title":"Natural killer cell membrane manipulation for augmented immune synapse and anticancer efficacy","volume":"33","author":"Ryu","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2026.103737_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101041","article-title":"The promising role of tumor-associated macrophages in the treatment of cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Drug Resist"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.mtbio.2026.103737_bib8","article-title":"Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy","volume":"4","author":"Yang","year":"2023","journal-title":"Mol. Ther. Oncolystics"},{"key":"10.1016\/j.mtbio.2026.103737_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2026.108871","article-title":"Synthetic biology-engineered immunotherapies: precision control of immune responses","author":"Wang","year":"2026","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103737_bib11","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the tumor microenvironment on NK cell function in solid tumors","volume":"10","author":"Melaiu","year":"2020","journal-title":"Front. Immunol."},{"issue":"111","key":"10.1016\/j.mtbio.2026.103737_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adv6870","article-title":"Inhibitory immune checkpoints in cancer immunotherapy","volume":"10","author":"Tang","year":"2025","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib13","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib15","article-title":"A comprehensive review of US FDA\u2010approved immune checkpoint inhibitors in urothelial carcinoma","volume":"2017","author":"Hsu","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A comprehensive review about the use of monoclonal antibodies in cancer therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib17","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1038\/s41467-023-41335-1","article-title":"A cytotoxic T cell inspired oncolytic nanosystem promotes lytic cell death by lipid peroxidation and elicits antitumor immune responses","volume":"14","author":"Zuo","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41568-025-00893-w","article-title":"Targeting phagocytosis checkpoints for cancer immunotherapy","volume":"26","author":"Veillette","year":"2026","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s44222-023-00148-z","article-title":"Biomaterials to enhance adoptive cell therapy","volume":"2","author":"Eckman","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40824-023-00369-8","article-title":"Emerging biomaterials for tumor immunotherapy","volume":"27","author":"Xiao","year":"2023","journal-title":"Biomater. Res."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib22","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1021\/acsnano.2c11691","article-title":"Boosting checkpoint immunotherapy with biomaterials","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400586","article-title":"Biomaterial\u2010Based therapeutic delivery of immune cells","volume":"14","author":"Dravid","year":"2025","journal-title":"Adv. Healthcare Mater."},{"issue":"14","key":"10.1016\/j.mtbio.2026.103737_bib24","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T\u2010cell engager) platform: development and future potential of a targeted immuno\u2010oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"issue":"41","key":"10.1016\/j.mtbio.2026.103737_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309697","article-title":"Targeting dual immune checkpoints PD\u2010L1 and HLA\u2010G by trispecific T cell engager for treating heterogeneous lung cancer","volume":"11","author":"Lin","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.103737_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1536569","article-title":"Aptamer based immunotherapy: a potential solid tumor therapeutic","volume":"16","author":"Mathavan","year":"2025","journal-title":"Front. Immunol."},{"issue":"27","key":"10.1016\/j.mtbio.2026.103737_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba8564","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"6","author":"Au","year":"2020","journal-title":"Sci. Adv."},{"issue":"37","key":"10.1016\/j.mtbio.2026.103737_bib28","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1039\/D2TB00583B","article-title":"Recent advances in biomaterial-assisted cell therapy","volume":"10","author":"Chen","year":"2022","journal-title":"J. Mater. Chem. B"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy","volume":"6","author":"Fuc\u00e0","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103737_bib32","first-page":"1","article-title":"How crosstalk at the immune synapse shapes T cell and dendritic cell biology","author":"Mart\u00edn-C\u00f3freces","year":"2026","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib33","article-title":"Potentiating anti-tumor immunity by re-engaging immune synapse molecules","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"8015","key":"10.1016\/j.mtbio.2026.103737_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41586-024-07439-4","article-title":"Structures of human \u03b3\u03b4 T cell receptor\u2013CD3 complex","volume":"630","author":"Xin","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115156","article-title":"The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity","volume":"44","author":"Pedroza","year":"2025","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib37","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.mtbio.2026.103737_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/imr.12107","article-title":"The central role of the cytoskeleton in mechanisms and functions of the NK cell immune synapse","volume":"256","author":"Lagrue","year":"2013","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mtbio.2026.103737_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2022.102112","article-title":"Building the phagocytic cup on an actin scaffold","volume":"77","author":"Krendel","year":"2022","journal-title":"Curr. Opin. Cell Biol."},{"issue":"24","key":"10.1016\/j.mtbio.2026.103737_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500575","article-title":"Strategies for the generation of bispecific antibodies","volume":"26","author":"Yuan","year":"2025","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12672-026-04735-5","article-title":"Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers","volume":"17","author":"Ardah","year":"2026","journal-title":"Discov. Oncol."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert Opin. Drug Discovery"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 co-engagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.mtbio.2026.103737_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2026.2622746","article-title":"Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety","author":"You","year":"2026","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2007-08-108050","article-title":"CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85\/p110 heterodimer","volume":"111","author":"Garcon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103737_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1129191","article-title":"NF\u03baB signaling in T cell memory","volume":"14","author":"Daniels","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103737_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727441","article-title":"Cell cycle entry control in na\u00efve and memory CD8+ T cells","volume":"9","author":"Lewis","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mtbio.2026.103737_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: a promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib53","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0171","article-title":"CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells","volume":"5","author":"Velasquez","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2256904","article-title":"Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer","volume":"19","author":"Huan","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.mtbio.2026.103737_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1483884","article-title":"Natural killer cell engagers for cancer immunotherapy","volume":"14","author":"Nikkhoi","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2026.103737_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2381261","article-title":"Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers","author":"Liao","year":"2024","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib57","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.4110\/in.2024.24.e34","article-title":"Current developments in NK cell engagers for cancer immunotherapy: focus on CD16A and NKp46","volume":"24","author":"Shin","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.mtbio.2026.103737_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1442673","article-title":"Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ijms19010092","article-title":"The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis","volume":"19","author":"Hirayama","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380142","article-title":"CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy","volume":"7","author":"Li","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.mtbio.2026.103737_bib63","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood.V90.11.4485","article-title":"Fc\u03b1RI (CD89) as a novel trigger molecule for bispecific antibody therapy","volume":"90","author":"Valerius","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib64","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mi.2011.36","article-title":"The human immunoglobulin A Fc receptor Fc\u03b1RI: a multifaceted regulator of mucosal immunity","volume":"4","author":"Bakema","year":"2011","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.mtbio.2026.103737_bib65","article-title":"Potential role of CD47-directed bispecific antibodies in cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103737_bib66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mtbio.2026.103737_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075595","article-title":"Novel CD47: sirp\u03b1 dependent mechanism for the activation of STAT3 in antigen-presenting cell","volume":"8","author":"Toledano","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib69","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib71","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/ph14090884","article-title":"Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib14010016","article-title":"Immune cell engagers: advancing precision immunotherapy for cancer treatment","volume":"14","author":"In","year":"2025","journal-title":"Antibodies"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib73","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2025","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.mtbio.2026.103737_bib74","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib75","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3324\/haematol.2024.285343","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.mtbio.2026.103737_bib76","article-title":"The evolving landscape of antibody-based cancer therapies: from monospecific to multi-specific and beyond","author":"Onyekachi","year":"2025","journal-title":"Crit. Rev. Oncol. Hemat."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.mtbio.2026.103737_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib79","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib80","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-025-02187-9","article-title":"Catumaxomab: first approval: YY syed","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib81","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond: translational therapeutics","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib82","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-025-02557-5","article-title":"A modular \u201cCatch-and-Play\u201d platform for rapid T-cell engager target assembly for personalised cancer treatment","volume":"11","author":"Xi","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103737_bib83","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/cancers17111820","article-title":"T-cell engager therapy in prostate cancer: molecular insights into a new frontier in immunotherapy","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib84","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1535-7163.MCT-25-0453","article-title":"Preclinical activity of the DLL3-Targeted T-cell engager MK-6070 in neuroendocrine prostate cancer","volume":"25","author":"Ku","year":"2026","journal-title":"Mol. Cancer. Ther."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/cells13100879","article-title":"Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma","volume":"13","author":"Grab","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.mtbio.2026.103737_bib86","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2024-204614","article-title":"First-in-Human phase 1 Study of SAR442257 in patients with Relapsed\/Refractory multiple myeloma and non-hodgkin lymphoma","volume":"144","author":"Schjesvold","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib87","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.mtbio.2026.103737_bib88","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2024-208189","article-title":"First results of a phase 1, first-in-human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting trispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Quach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103737_bib89","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025030027","article-title":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models","volume":"147","author":"Pillarisetti","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103737_bib90","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2025-702","article-title":"Initial results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib91","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-23-0692","article-title":"The CD33xCD123xCD70 multispecific CD3-engaging DARPin MP0533 induces selective T cell\u2013mediated killing of AML leukemic stem cells","volume":"12","author":"Bianchi","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.mtbio.2026.103737_bib92","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2024-199211","article-title":"MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the treatment of patients with relapsed\/refractory AML or MDS\/AML: results of an ongoing phase 1\/2a study","volume":"144","author":"Jongen-Lavrencic","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103737_bib93","article-title":"GNC-038, a tetra-specific antibody, in patients with R\/R non-hodgkin lymphoma or acute lymphoblastic leukemia: a phase 1 study design and rationale","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103737_bib94","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/blood-2025-3311","article-title":"MDX2003, a novel tetraspecific T cell engager-expander targeting CD19xCD20xCD3xCD28, demonstrates potent preclinical activity against B cell malignancies","volume":"146","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103737_bib95","first-page":"1","article-title":"MDX-2001\u2013101 study protocol: a phase I\/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors","author":"Dumbrava","year":"2026","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13435","article-title":"Recognition of self and viral ligands by NK cell receptors","volume":"329","author":"Mariuzza","year":"2025","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib97","article-title":"Targeting BCMA in multiple myeloma with a trifunctional NK cell engager","volume":"7","author":"Tang","year":"2026","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010179","article-title":"Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer","volume":"13","author":"Tinoco","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"116","key":"10.1016\/j.mtbio.2026.103737_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aef9200","article-title":"The dark side of the dot: how melanosomes dim T cell activity","volume":"11","author":"Wang","year":"2026","journal-title":"Sci. Immunol."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib100","first-page":"274","article-title":"Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells","volume":"28","author":"Vallera","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Targeted Oncol."},{"issue":"14","key":"10.1016\/j.mtbio.2026.103737_bib102","first-page":"3844","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16\u00d7 33 bispecific killer cell engager and ADAM17 inhibition, Clinc","volume":"19","author":"Wiernik","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103737_bib103","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","author":"Reusch","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.mtbio.2026.103737_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2315640","article-title":"Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers","author":"Boje","year":"2024","journal-title":"mAbs"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib105","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","article-title":"Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity","volume":"177","author":"Gauthier","year":"2019","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.mtbio.2026.103737_bib106","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib107","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"Suppl.1","key":"10.1016\/j.mtbio.2026.103737_bib108","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood-2023-185432","article-title":"Preclinical characterization of the anti-leukemia activity of the CD33\/CD16\/NKG2D immune modulating TriNKET \u00ae BMS-986357 (CC-96191)","volume":"142","author":"Lunn","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib109","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/cancers12092659","article-title":"NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo","volume":"12","author":"Vallera","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"issue":"45","key":"10.1016\/j.mtbio.2026.103737_bib111","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12073","article-title":"Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker","volume":"7","author":"Schmohl","year":"2016","journal-title":"Oncotarget"},{"issue":"101","key":"10.1016\/j.mtbio.2026.103737_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp3720","article-title":"A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-hodgkin lymphoma","volume":"9","author":"Demaria","year":"2024","journal-title":"Sci. Immunol."},{"issue":"12","key":"10.1016\/j.mtbio.2026.103737_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005447","article-title":"Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade","volume":"10","author":"Xu","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib114","first-page":"217","article-title":"CD89: the human myeloid IgA Fc receptor","volume":"49","author":"Morton","year":"2001","journal-title":"Arch. Immunol. Ther. Exp. English Edition"},{"key":"10.1016\/j.mtbio.2026.103737_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151761","article-title":"Targeting ALPPL2 with a novel CD89 bispecific antibody reprograms macrophages to enhance anti-tumor immunity","volume":"762","author":"Xu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"20","key":"10.1016\/j.mtbio.2026.103737_bib116","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/0008-5472.CAN-20-1418","article-title":"ALPPL2 is a highly specific and targetable tumor cell surface antigen","volume":"80","author":"Su","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib117","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13036-025-00580-2","article-title":"Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy","volume":"19","author":"Lee","year":"2025","journal-title":"J. Biol. Eng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antib7010003","article-title":"Tumor-directed blockade of CD47 with bispecific antibodies induces adaptive antitumor immunity","volume":"7","author":"Dheilly","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.mtbio.2026.103737_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151955","article-title":"Dual targeting of ENPP3 and SIRP\u03b1 with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma","volume":"769","author":"Xu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mtbio.2026.103737_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119609","article-title":"Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)","volume":"200","author":"Muneekaew","year":"2026","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib121","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib122","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbrc.2008.02.111","article-title":"Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs","volume":"369","author":"Ando","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib123","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib124","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib126","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1039\/C5AN01824B","article-title":"Aptamers in analytics","volume":"141","author":"Ilgu","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.mtbio.2026.103737_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102552","article-title":"Antibody and aptamer-based therapies for osteoarthritis: application of antibodies and promise of aptamers","volume":"36","author":"Chen","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib129","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/acs.bioconjchem.0c00071","article-title":"Construction of bispecific aptamer\u2013drug conjugate by a hybrid chemical and biological approach","volume":"31","author":"Sun","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.mtbio.2026.103737_bib130","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtn.2022.01.008","article-title":"Cancer immunomodulation using bispecific aptamers","volume":"27","author":"Thomas","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103737_bib132","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.omtn.2022.01.010","article-title":"CD16\/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade","volume":"27","author":"Zheng","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib133","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/mt.2011.145","article-title":"Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers","volume":"19","author":"Pastor","year":"2011","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib134","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/molecules24030478","article-title":"Novel bispecific aptamer enhances immune cytotoxicity against MUC1-positive tumor cells by MUC1-CD16 dual targeting","volume":"24","author":"Li","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib131","article-title":"The emerging role of aptamers in targeted cancer immunotherapy","volume":"34","author":"Zhu","year":"2026","journal-title":"Mol. Ther. Oncol."},{"issue":"24","key":"10.1016\/j.mtbio.2026.103737_bib135","doi-asserted-by":"crossref","first-page":"21896","DOI":"10.1074\/jbc.M111.238261","article-title":"Bi-specific aptamers mediating tumor cell lysis","volume":"286","author":"Boltz","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.mtbio.2026.103737_bib136","doi-asserted-by":"crossref","first-page":"11279","DOI":"10.1039\/D1NR00836F","article-title":"Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer","volume":"13","author":"Zheng","year":"2021","journal-title":"Nanoscale"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib137","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1021\/acsnano.9b09884","article-title":"Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy","volume":"14","author":"Yang","year":"2020","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib138","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/2326-6066.CIR-14-0007","article-title":"Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy","volume":"2","author":"Schrand","year":"2014","journal-title":"Cancer Immnol. Res."},{"issue":"17","key":"10.1016\/j.mtbio.2026.103737_bib139","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8095","article-title":"MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells","volume":"7","author":"Soldevilla","year":"2016","journal-title":"Oncotarget"},{"issue":"50","key":"10.1016\/j.mtbio.2026.103737_bib140","doi-asserted-by":"crossref","first-page":"34311","DOI":"10.1021\/jacs.4c06189","article-title":"Programmable circular multispecific aptamer-drug engager to broadly boost antitumor immunity","volume":"146","author":"Chen","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib141","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CJI.0b013e3181dda225","article-title":"Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16","volume":"33","author":"Singer","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.mtbio.2026.103737_bib142","doi-asserted-by":"crossref","first-page":"366","DOI":"10.34133\/bmr.0366","article-title":"Amphiphilic Lipid\u2013Single-Stranded DNA conjugate-mediated cell surface engineering for programmable intercellular tethering and immune synapse formation","volume":"30","author":"Kim","year":"2026","journal-title":"Biomater. Res."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib143","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.mtbio.2026.103737_bib144","article-title":"Lipid-mediated ex vivo cell surface engineering for augmented cellular functionalities","volume":"140","author":"Kim","year":"2022","journal-title":"Biomater. Adv."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40824-023-00404-8","article-title":"Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics","volume":"27","author":"Jangid","year":"2023","journal-title":"Biomater. Res."},{"issue":"24","key":"10.1016\/j.mtbio.2026.103737_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202306738","article-title":"Surface engineering of natural killer cells with CD44\u2010targeting ligands for augmented cancer immunotherapy","volume":"20","author":"Kim","year":"2024","journal-title":"Small"},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib147","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/acs.bioconjchem.3c00335","article-title":"Biomaterial-mediated exogenous facile coating of natural killer cells for enhancing anticancer efficacy toward hepatocellular carcinoma","volume":"34","author":"Jangid","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib148","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/acs.biomac.3c00916","article-title":"Ex vivo surface decoration of phenylboronic acid onto natural killer cells for sialic acid-mediated versatile cancer cell targeting","volume":"25","author":"Jangid","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.mtbio.2026.103737_bib149","article-title":"Dual-ligand engineering of NK cell surfaces using lipid conjugates: harnessing bispecific targeting to CD44 and sialic acid for solid tumor treatment","author":"Park","year":"2026","journal-title":"Chem. Eng. J."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103737_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201800447","article-title":"One-step method for instant generation of advanced allogenic NK cells","volume":"5","author":"Lee","year":"2018","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib151","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/pharmaceutics17101285","article-title":"Surface engineering of naturall killer cells with lipid-based antibody capture platform for targeted chemoimmunotherapy","volume":"17","author":"Lim","year":"2025","journal-title":"Pharmacuetics"},{"issue":"14","key":"10.1016\/j.mtbio.2026.103737_bib152","article-title":"Membrane\u2010fusion\u2010mediated multiplex engineering of tumor cell surface glycans for enhanced NK cell therapy","volume":"35","author":"Zheng","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103737_bib153","article-title":"Fusogenic liposome-engineered natural killer cells for solid tumor therapy","author":"Zheng","year":"2026","journal-title":"Cell Biomat"},{"issue":"23","key":"10.1016\/j.mtbio.2026.103737_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400970","article-title":"Click chemistry\u2010mediated polymannose surface\u2010engineering of natural killer cells for immunotherapy of triple\u2010negative breast cancer","volume":"13","author":"Niu","year":"2024","journal-title":"Adv. Healthcare Mater."},{"issue":"45","key":"10.1016\/j.mtbio.2026.103737_bib155","article-title":"Nanobody\u2010engineered natural killer cell conjugates for solid tumor adoptive immunotherapy","volume":"17","author":"Gong","year":"2021","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201804383","article-title":"Bio\u2010orthogonal T cell targeting strategy for robustly enhancing cytotoxicity against tumor cells","volume":"15","author":"Li","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2026.103737_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.145211","article-title":"Lipid anchor-mediated NK cell surface engineering for enhanced cancer immunotherapy","volume":"473","author":"Kim","year":"2023","journal-title":"Chem. Eng. J."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib158","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40580-023-00406-1","article-title":"Tailoring tumor-recognizable hyaluronic acid\u2013lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells","volume":"10","author":"Lee","year":"2023","journal-title":"Nano Converg."},{"issue":"3","key":"10.1016\/j.mtbio.2026.103737_bib159","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1021\/acs.biomac.3c01373","article-title":"Optimized design of hyaluronic acid\u2013lipid conjugate biomaterial for augmenting CD44 recognition of surface-engineered NK cells","volume":"25","author":"Park","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.mtbio.2026.103737_bib160","article-title":"Immune cell surface functionalization strategies for potentiating cell-based therapy against solid tumors","author":"Wang","year":"2026","journal-title":"Chem. Eng. J."},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib161","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1039\/b913621e","article-title":"Cell surface modification with polymers for biomedical studies","volume":"6","author":"Teramura","year":"2010","journal-title":"Soft Matter"},{"issue":"15","key":"10.1016\/j.mtbio.2026.103737_bib162","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1038\/emboj.2011.215","article-title":"A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans","volume":"30","author":"Tsuboi","year":"2011","journal-title":"The EMBO journal"},{"key":"10.1016\/j.mtbio.2026.103737_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108467","article-title":"Implications of glycosylation for the development of selected cytokines and their derivatives for medical use","volume":"77","author":"Scapin","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.mtbio.2026.103737_bib164","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1655750","article-title":"Metabolic glycoengineering: a promising strategy to remodel microenvironments for regenerative therapy","author":"Li","year":"2023","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.mtbio.2026.103737_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.148120","article-title":"Bioorthogonal chemistry mediated cell engineering for advanced cell and cell-derived vesicle therapies: principles, progresses, and remaining challenges","volume":"480","author":"Pan","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib166","doi-asserted-by":"crossref","DOI":"10.1063\/5.0050850","article-title":"Azide-based bioorthogonal chemistry: reactions and its advances in cellular and biomolecular imaging","volume":"2","author":"Alamudi","year":"2021","journal-title":"Biophysics Reviews"},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505387","article-title":"T cell glycoengineering to modulate immune\u2010tumor crosstalk: a universal non\u2010genetic strategy for enhanced tumor immunotherapy","volume":"13","author":"Yao","year":"2026","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib168","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1038\/s41467-023-42725-1","article-title":"An in situ dual-anchoring strategy for enhanced immobilization of PD-L1 to treat autoimmune diseases","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib169","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s44222-022-00016-2","article-title":"Targeted modulation of immune cells and tissues using engineered biomaterials","volume":"1","author":"Yousefpour","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib170","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-021-21497-6","article-title":"Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib171","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/cells11010159","article-title":"Aptamer-enabled nanomaterials for therapeutics, drug targeting and imaging","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib172","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2004.02.029","article-title":"Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes","volume":"97","author":"Tabatt","year":"2004","journal-title":"J. Controlled Release"},{"issue":"16","key":"10.1016\/j.mtbio.2026.103737_bib173","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/nano15161262","article-title":"Advancements in tumor-targeted nanoparticles: design strategies and multifunctional therapeutic approaches","volume":"15","author":"Li","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.mtbio.2026.103737_bib174","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jconrel.2023.07.020","article-title":"Controlled spatial characteristics of ligands on nanoparticles: determinant of cellular functions","volume":"360","author":"Choi","year":"2023","journal-title":"J. Controlled Release"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib175","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1021\/acsnano.6b08152","article-title":"Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth","volume":"11","author":"Kosmides","year":"2017","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib176","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1038\/s41467-024-50474-y","article-title":"Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103737_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102075","article-title":"Protein cage nanoparticle-based NK cell-engaging nanodrones (NKeNDs) effectively recruit NK cells to target tumor sites and suppress tumor growth","volume":"54","author":"Park","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.mtbio.2026.103737_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101313","article-title":"Bi-specific macrophage nano-engager for cancer immunotherapy","volume":"41","author":"Zhao","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.mtbio.2026.103737_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.150068","article-title":"Bi-specific nanoparticle-based engager capable of in situ activation of anti-tumor immune responses for postoperative cancer immunotherapy","volume":"485","author":"Hao","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"21","key":"10.1016\/j.mtbio.2026.103737_bib180","doi-asserted-by":"crossref","first-page":"15230","DOI":"10.1021\/acsnano.6c01144","article-title":"Bispecific macrophage nano-engager couples dual checkpoint blockade with stimulator of Interferon genes activation to potentiate antitumor immunity","volume":"20","author":"Dang","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103737_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.149901","article-title":"A STING agonist-loaded bispecific nanobioconjugate modulates macrophage immune responses to enhance antitumor immunotherapy","volume":"485","author":"Nie","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib182","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/s41375-021-01127-2","article-title":"Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy","volume":"35","author":"Alhallak","year":"2021","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.mtbio.2026.103737_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202202603","article-title":"In situ activated NK cell as bio\u2010orthogonal targeted live\u2010cell nanocarrier augmented solid tumor immunotherapy","volume":"32","author":"Meng","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.mtbio.2026.103737_bib184","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.addr.2020.09.003","article-title":"When liposomes met antibodies: drug delivery and beyond","volume":"154","author":"Di","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18","key":"10.1016\/j.mtbio.2026.103737_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810009","article-title":"Nanoparticles targeting innate immune cells in tumor microenvironment","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.mtbio.2026.103737_bib186","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.3390\/polym17222979","article-title":"PEGylation enhances colloidal stability and promotes ligand-mediated targeting of LAF\u2013Xenopeptide mRNA complexes","volume":"17","author":"Folda","year":"2025","journal-title":"Polymers"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib187","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41565-024-01620-6","article-title":"Chimeric nanobody-decorated liposomes by self-assembly","volume":"19","author":"Rahman","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103737_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115205","article-title":"Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy","author":"Xie","year":"2022","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib189","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12951-024-02781-1","article-title":"A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects","volume":"22","author":"Xie","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib190","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.mtbio.2026.103737_bib191","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41551-024-01230-6","article-title":"Cell\u2013drug conjugates","volume":"8","author":"Wang","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib192","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12951-026-04028-7","article-title":"Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration","volume":"24","author":"Sheng","year":"2026","journal-title":"J. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.mtbio.2026.103737_bib193","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.drudis.2020.06.029","article-title":"Engineering extracellular matrix to improve drug delivery for cancer therapy","volume":"25","author":"He","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.mtbio.2026.103737_bib194","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2016.04.021","article-title":"Drug delivery with living cells","volume":"106","author":"Fliervoet","year":"2016","journal-title":"Adv. Drug Delivery Rev."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7150\/thno.11852","article-title":"Cell or cell membrane-based drug delivery systems","volume":"5","author":"Tan","year":"2015","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib196","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","article-title":"Interleukin\u201021 activates human natural killer cells and modulates their surface receptor expression","volume":"123","author":"Skak","year":"2008","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib197","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mtbio.2026.103737_bib198","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12951-022-01480-z","article-title":"Dual-binding nanoparticles improve the killing effect of T cells on solid tumor","volume":"20","author":"Luo","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib199","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.mtbio.2026.103737_bib200","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70078","article-title":"CD16A shedding regulates innate cell engager-induced serial killing by natural killer cells","volume":"55","author":"Zambarda","year":"2025","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.mtbio.2026.103737_bib201","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cnma.201600047","article-title":"Cell surface engineering to control cellular interactions","volume":"2","author":"Custodio","year":"2016","journal-title":"ChemNanoMat"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103737_bib202","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3390\/pharmaceutics14122605","article-title":"Biological features of nanoparticles: protein corona formation and interaction with the immune system","volume":"14","author":"Panico","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103737_bib203","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.mtbio.2026.103737_bib204","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.mtbio.2026.103737_bib205","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nano.2012.05.015","article-title":"Effect of ligand density, receptor density, and nanopariticle size on cell targeting","volume":"9","author":"Elias","year":"2013","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.mtbio.2026.103737_bib206","doi-asserted-by":"crossref","first-page":"541","DOI":"10.20892\/j.issn.2095-3941.2025.0737","article-title":"Design principles of nanomaterials for cancer immunotherapy: a mechanistic framework across the cancer immunity cycle","volume":"23","author":"Bai","year":"2026","journal-title":"Cancer Biol. Med."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib207","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.ymthe.2017.06.003","article-title":"Quantitative imaging approaches to study the CAR immunological synapse","volume":"25","author":"Mukherjee","year":"2017","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.mtbio.2026.103737_bib208","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00262-025-04036-w","article-title":"Immunological synpase formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity","volume":"74","author":"Nakamura","year":"2025","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426009828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:39:10Z","timestamp":1793810350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426009828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":208,"alternative-id":["S2590006426009828"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103737","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering immune cell engagers: From molecular constructs to biomaterial platforms","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103737"}}